“The relationship between higher concentrations of EPA and a decreased risk for incident all-cause dementia was significant among APOE e4 noncarriers (Model 2: HR = 0.76, 95% CI 0.61, 0.94) but not among APOE e4 carriers (Table S4). Furthermore, higher concentrations and higher proportions of EPA were associated with a decreased risk for incident AD dementia among APOE e4 noncarriers (concentrations, Model 2: HR = 0.66, 95% CI 0.51, 0.84; proportions, Model 2: HR = 0.80, 95% CI 0.65, 0.99) but not among APOE e4 carriers”
Findings from this study may be of some concern because I believe BRAVE includes APOE e4 carriers.